Abstract.
We herein report familial defects in the molecular structure of luteinizing hormone (LH LUTEINIZING hormone (LH) is secreted from the anterior lobe of pituitary gland and promotes ovulation with follicle-stimulation hormone (FSH) by stimulating the ovaries to synthesize steroids in women [1] . The defect in LH has been referred to as a quantitative abnormality, such as hypogonadotropic hypogonadism [2] and polycystic ovary syndrome [3] . Recently, an abnormality in the quality of LH has been proposed by several investigators [4] [5] [6] , but the exact pathogenesis has not been clarified.
We report here a propositus in whom the serum Her external genitals and vagina were normal. Hysterosalpingography showed a normally shaped uterine cavity, and both patent tubes. Hysteroscopic examination also found no abnormalities in the uterine cavity. The husband's karyotype was also normal (46, XY), and his semen analysis was normozoospermic.
As shown in Fig. 1 , the chart of basal body temperature of the propositus showed an ovulatory cycle without any medication.
The propositus was treated with 2.5 mg/day of bromocriptine for 2 months because of a masked hyperprolactinemia. Plasma progesterone levels were 16.1 and 16.8 ng/ ml in the mid luteal phase. At the same time, she was found to have an extremely low serum concentration of LH (less than 0.5 IU/L) determined with a SPAC-S kit. On September 24th, the conception was diagnosed by urinary hCG measure- sults, the serum LH concentration was measured by the following four assays. The concentrations of LH in the serum of the propositus collected on various days of the menstrual cycle were between 1.1 IU / L and 19.0 IU / L as determined with an LH SEROZYME kit (Serono, Switzerland) which is for the enzyme immunoassay (EIA), but LH was not detected with the SPAC-S kit (Table 1) or the RIAgnost kit (Behring Werke A.G., Germany) using two different monoclonal antibodies for the fl-subunit of LH (data not shown). We next employed the IMX kit (EIA) utilizing a monoclonal antibody for 13-specific solid phase and polyclonal antibody for LH. The concentration of serum LH in the propositus was 6.3 IU/L determined with the IMX kit. These immunoassays of LH were calibrated against WHO IRP 1st IRP 68/40. The concentration of LH was 10.0 IU / L as measured with a competitive radioimmunoassay LH Kit "Daiichi" (Daiichi Radioisotope Lab, Japan). This kit used a polyclonal antibody for LH and 2nd IRP-HMG (67/161) for standard LH.
To examine whether the sugar chain of LH is abnormal, the serum of the propositus was treated with almond glycopeptidase [7] to digest the sugar chains of LH. The serum LH in the subject after Table 1 .
The serum concentrations of LH, FSH, estradiol, progesterone in the propositus in the clinical course
The names of the assay kits used are indicated in the parenthesis. Values are determined by SPAC-S kit (LH-SPAC), IMX kit (LH-IMX) and bioassay (LH-Bio). The ratio is calculated and shown in this table. Pedigree analysis of the propositus with respect to LH detectability with IFMA (SPAC-S kit) relative to Bioassay (LH-Bio).
The ratio of the LH concentrations (LH-SPAC/LH-Bio) was below 0.04 in the propositus and her brother. The parents and sister had moderately d ecreased ratios (0.11-0.17) compared to the normal ratio. 
